Amryt Pharma plc is a commercial-stage biopharmaceutical company committed to enhancing the lives of individuals with rare and orphan diseases. The firm achieves this by acquiring, developing, and bringing to market specialized therapies. Among its current offerings, Amryt provides: Metreleptin, prescribed as a dietary adjunct and replacement therapy, addresses complications arising from leptin deficiency in patients with congenital or acquired generalized lipodystrophy.